Ocumension Therapeutics (HKSE:01477) Total Inventories : HK$35.5 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Total Inventories?

Ocumension Therapeutics's total inventories for the quarter that ended in Dec. 2023 was HK$35.5 Mil. Ocumension Therapeutics's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was HK$33.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ocumension Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$1.26.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ocumension Therapeutics's Days Inventory for the six months ended in Dec. 2023 was 91.80.

Inventory Turnover measures how fast the company turns over its inventory within a year. Ocumension Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.99.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ocumension Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.22.

Ocumension Therapeutics Total Inventories Historical Data

The historical data trend for Ocumension Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Total Inventories Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

0.29

3.59

6.11

26.92

35.52

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial						6.11	27.92	26.92	31.62	35.52

Ocumension Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Ocumension Therapeutics (HKSE:01477) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Ocumension Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1147.922	+	0.75 * 121.367	+	0.5 * 35.518	-	383.95
-	0	-	0)	/	690.904
=	1.26

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ocumension Therapeutics's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	33.5705	/	66.738	*	365 / 2
	=	91.80

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ocumension Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	66.738	/	33.5705
	=	1.99

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ocumension Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	33.5705	/	156.051
	=	0.22

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Ocumension Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines